Parallax Volatility Advisers, L.P. Blueprint Medicines Corp Transaction History

Parallax Volatility Advisers, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $156,125 - $207,629	-2,123 Reduced 77.51%	616 $58,000
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $453,689 - $806,765	-9,316 Reduced 77.28%	2,739 $219,000
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $422,433 - $688,390	9,270 Added 332.85%	12,055 $650,000
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $169,773 - $281,786	2,785 New	2,785 $177,000
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $473,975 - $665,880	-6,468 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $406,901 - $571,253	6,468	6,468 $488,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.